SCHOLZ, Alexander, WEYERBROCK, Astrid und REISS, Yvonne, 2021. Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma. Freiburg: Universität.
Elsevier - Harvard (with titles)Scholz, A., Weyerbrock, A., Reiss, Y., 2021. Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma. Universität, Freiburg. https://doi.org/10.15252/emmm.201505505
American Psychological Association 7th editionScholz, A., Weyerbrock, A., & Reiss, Y. (ca. 2021). Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma [Cd]. Universität. https://doi.org/10.15252/emmm.201505505
Springer - Basic (author-date)Scholz A, Weyerbrock A, Reiss Y (2021) Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma. Universität, Freiburg
Juristische Zitierweise (Stüber) (Deutsch)Scholz, Alexander/ Weyerbrock, Astrid/ Reiss, Yvonne, Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma, Freiburg 2021.